- ISIN
- US45032V1089
- CUSIP
- 45032V108
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jun 17, 2021
Highlights
- EPS (TTM)
- -$2.77
- Total Revenue (TTM)
- $3.35M
- Gross Profit (TTM)
- $722.54K
- EBITDA (TTM)
- -$9.47M
- Year Range
- $2.45 - $127.20
- ROA (TTM)
- -121.00%
- ROE (TTM)
- -373.45%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ISPC Performance Chart
iSpecimen Inc. (ISPC) is down 75.8% since the beginning of the year. At $3 per share, ISPC is trading 98.0% below its 52-week high of $127. Investors who bought $1,000 worth of ISPC shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
iSpecimen Inc. (ISPC) has returned -75.78% so far this year and -93.44% over the past 12 months.
iSpecimen Inc.
- 1D
- -2.70%
- 1M
- -26.96%
- YTD
- -75.78%
- 6M
- -83.06%
- 1Y
- -93.44%
- 3Y*
- -86.86%
- 5Y*
- -78.33%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ISPC Monthly Returns History
Based on dividend-adjusted daily data since Jun 17, 2021, ISPC's average daily return is -0.23%, while the average monthly return is -7.09%.
Historically, 30% of months were positive and 70% were negative. The best month was Nov 2021 with a return of +145.9%, while the worst month was Dec 2021 at -57.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ISPC closed higher 40% of trading days. The best single day was Sep 9, 2025 with a return of +159.7%, while the worst single day was Sep 10, 2025 at -32.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 34.99% | -28.80% | -37.20% | -16.72% | -39.58% | -20.25% | -75.78% | ||||||
| 2025 | -25.05% | -16.58% | -36.14% | 19.81% | -3.94% | -19.67% | 26.53% | -42.64% | 81.36% | -39.54% | -46.13% | -38.09% | -90.20% |
| 2024 | -3.62% | -6.74% | -48.44% | 25.43% | 47.73% | -28.12% | -14.24% | 1.89% | -12.96% | -8.94% | 0.23% | -38.11% | -73.48% |
| 2023 | 22.91% | -3.55% | -17.79% | 15.80% | -14.29% | 7.52% | 7.69% | -43.50% | -28.74% | -8.06% | -1.77% | -10.59% | -63.59% |
| 2022 | -37.39% | -15.95% | 30.66% | -40.60% | -5.96% | -27.33% | 7.80% | -6.81% | -24.66% | -3.64% | -1.26% | -12.42% | -82.39% |
| 2021 | 15.15% | -13.02% | 8.12% | -14.06% | 28.71% | 145.94% | -57.72% | 24.56% |
Benchmark Metrics
iSpecimen Inc. has an annualized alpha of -50.23%, beta of 0.90, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 17, 2021.
- This stock participated in 247.25% of S&P 500 Index downside but only -106.55% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -50.23%
- Beta
- 0.90
- R²
- 0.01
- Upside Capture
- -106.55%
- Downside Capture
- 247.25%
Return for Risk
Risk / Return Rank
ISPC ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for iSpecimen Inc. (ISPC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ISPC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.47 | ||
| Sortino ratioReturn per unit of downside risk | -3.83 | ||
| Omega ratioGain probability vs. loss probability | 0.88 | 1.37 | -0.49 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 2.78 | -3.75 |
| Martin ratioReturn relative to average drawdown | -1.29 | 12.44 | -13.73 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the iSpecimen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the iSpecimen Inc. was 99.98%, occurring on Jun 22, 2026. The portfolio has not yet recovered.
The current iSpecimen Inc. drawdown is 99.98%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.98%Jun 2026 | 4y 6mo | — | 4y 6moNov 2021 - now |
2021 bear market2021 | -42.31%Nov 2021 | 4mo 20d | 5d | 4mo 25dJun 2021 - Nov 2021 |
2021 bear market2021 | -22.67%Nov 2021 | 0s | 2d | 2dNov 2021 - Nov 2021 |
2021 correction2021 | -15.75%Jun 2021 | 3d | 4d | 7dJun 2021 - Jun 2021 |
Drawdown Indicators
| ISPC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -96.77% | -9.10% | -87.67% |
Max Drawdown (3Y)Largest decline over 3 years | -99.81% | -18.90% | -80.91% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -25.43% | -74.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.98% | -1.80% | -98.18% |
Average DrawdownAverage peak-to-trough decline | -87.61% | -10.71% | -76.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 72.14% | 2.03% | +70.11% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of iSpecimen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how iSpecimen Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ISPC relative to other companies in the Diagnostics & Research industry. Currently, ISPC has a P/S ratio of 3.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ISPC
Add iSpecimen Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ISPC